tissues of bone marrow and blood vessels, adipose tissue, and placental tissue, have been highly approved as a particularly attractive autologous cell source for the purpose of regenerative therapy in the past decade. Accordingly, we opened up a special issue focused on TDSCs in 2016 with a large yield in appealing findings and correlated mechanisms though the safety aspects of their clinical applicability need to be well investigated and assessed in further study. In the meanwhile, the high risk of malignant transformation emerged as a critical obstacle to safe clinical translation of embryonic stem cell-or induced pluripotent stem cell-based therapies despite their fascinating differentiation potentials. Therefore, the compromising but feasible strategy of current regenerative therapies aimed at clinical applications is mostly limited to TDSCs isolated from adult tissue including bone marrow, adipose tissues, and placental tissues, which in comparison with totipotent stem cells have more specialization and less differentiation potential. In view of novel strategy and improved technique in the recent studies of TDSCs, we pushed forward a serial special issue in 2017.
Eighteen selected papers of research and review were published in this special issue according to the topics. In terms of the source of TDSCs, thirteen groups reported their studies in mesenchymal stem cells (MSCs) derived from bone marrow, adipose, lung, endometrium, placenta, and gingiva; three groups in stem cells derived from midbrain, limbal epithelial cell, and urine; one group in umbilical cord blood; and one group in hepatic progenitor cells.
Though the previous studies have demonstrated the efficacy of bone marrow-derived MSCs in graft-versus-host disease, osteogenesis imperfecta, myocardial infarction, systemic lupus erythematosus, and diabetes in both preclinical and early-phase clinical studies, the difference and the elucidating mechanisms of immune phenotype and proliferative potential between the bone marrow-and other source- In conclusion, it is entirely possible that TDSCs come to be the feasible and novel source into clinical regenerative trials in the near future encouraged by the fascinating observations from the original research articles as well as the review articles collected in this special issue. However, there still remain fundamental uncertainties including elucidation to mechanisms, safety aspects, and reproducibility regarding the variety of origin of stem cells.
